Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Effect of dapagliflozin on renal haemodynamics in hyperfiltering T2D patients

View through CrossRef
Abstract Aims To investigate the effect of sodium‐glucose co‐transporter 2 inhibitor [SGLT‐2i] therapy on renal haemodynamics in T2D patients with glomerular hyperfiltration. Materials and Methods Sixty T2D patients with elevated [HYPER] and normal [NORMO] GFR were randomized to dapagliflozin 10 mg/day [DAPA/HYPER, n  = 15; DAPA/NORMO, n  = 15] or to metformin/glipizide [CONTROL/HYPER, n  = 15; CONTROL/NORMO, n  = 15] to reach similar glycaemic control after 4 months. GFR was measured with Iohexol and hyperfiltration was empirically defined as >125 mL/min/1.73 m 2 . GFR, renal plasma flow [RPF], mean arterial pressure [MAP], filtration fraction [FF], and renal vascular resistance [RVR] were determined before/after therapy. Results HbA1c decreased similarly in all 4 groups. GFR declined by ~18% in DAPA/HYPER and by ~7% in DAPA/NORMO and did not change in CONTROLS ( p  < 0.05 vs. DAPA). RPF remained unchanged in all four groups. Thus, FF (%) declined from 0.23 ± 0.01 to 0.18 ± 0.01 in DAPA/HYPER and from 0.17 ± 0.01 to 0.15 ± 0.01 in DAPA/NORMO and remained unchanged in CONTROLS ( p  < 0.05 vs. DAPA). MAP (mmHg) decreased from 95.4 ± 1.4 to 88.1 ± 1.3 in DAPA/HYPER and from 95.6 ± 1.3 to 91.8 ± 0.8 in DAPA/NORMO and remained unchanged in CONTROLS ( p  < 0.05 vs. DAPA). RVR [mmHg/L/min] declined in DAPA/HYPER (92.7 ± 7.8 to 80.4 ± 6.1) and DAPA/NORMO (90.1 ± 3.0 to 81.4 ± 2.1) but not in CONTROLS ( p  < 0.05 vs. DAPA). Conclusions Despite comparable glycaemic control, dapagliflozin treatment, but not metformin and /or glipizide, reduced glomerular hyperfiltration in T2D patients and decreased both filtration fraction and renal vascular resistance. These findings suggest that a post‐glomerular vasodilatory action of SGLT2 inhibitors contributes to their renal protective effect in T2D.
Title: Effect of dapagliflozin on renal haemodynamics in hyperfiltering T2D patients
Description:
Abstract Aims To investigate the effect of sodium‐glucose co‐transporter 2 inhibitor [SGLT‐2i] therapy on renal haemodynamics in T2D patients with glomerular hyperfiltration.
Materials and Methods Sixty T2D patients with elevated [HYPER] and normal [NORMO] GFR were randomized to dapagliflozin 10 mg/day [DAPA/HYPER, n  = 15; DAPA/NORMO, n  = 15] or to metformin/glipizide [CONTROL/HYPER, n  = 15; CONTROL/NORMO, n  = 15] to reach similar glycaemic control after 4 months.
GFR was measured with Iohexol and hyperfiltration was empirically defined as >125 mL/min/1.
73 m 2 .
GFR, renal plasma flow [RPF], mean arterial pressure [MAP], filtration fraction [FF], and renal vascular resistance [RVR] were determined before/after therapy.
Results HbA1c decreased similarly in all 4 groups.
GFR declined by ~18% in DAPA/HYPER and by ~7% in DAPA/NORMO and did not change in CONTROLS ( p  < 0.
05 vs.
DAPA).
RPF remained unchanged in all four groups.
Thus, FF (%) declined from 0.
23 ± 0.
01 to 0.
18 ± 0.
01 in DAPA/HYPER and from 0.
17 ± 0.
01 to 0.
15 ± 0.
01 in DAPA/NORMO and remained unchanged in CONTROLS ( p  < 0.
05 vs.
DAPA).
MAP (mmHg) decreased from 95.
4 ± 1.
4 to 88.
1 ± 1.
3 in DAPA/HYPER and from 95.
6 ± 1.
3 to 91.
8 ± 0.
8 in DAPA/NORMO and remained unchanged in CONTROLS ( p  < 0.
05 vs.
DAPA).
RVR [mmHg/L/min] declined in DAPA/HYPER (92.
7 ± 7.
8 to 80.
4 ± 6.
1) and DAPA/NORMO (90.
1 ± 3.
0 to 81.
4 ± 2.
1) but not in CONTROLS ( p  < 0.
05 vs.
DAPA).
Conclusions Despite comparable glycaemic control, dapagliflozin treatment, but not metformin and /or glipizide, reduced glomerular hyperfiltration in T2D patients and decreased both filtration fraction and renal vascular resistance.
These findings suggest that a post‐glomerular vasodilatory action of SGLT2 inhibitors contributes to their renal protective effect in T2D.

Related Results

Beyond the ivory tower
Beyond the ivory tower
Type 2 diabetes mellitus (T2D) is a leading cause of disability and mortality in the United States, and is responsible for $327 billion annually in economic damage. The presence of...
527-P: Renal Hemodynamic and RAAS Profiles in Patients with Type 2 Diabetes (T2D) and Heart Failure (HF)
527-P: Renal Hemodynamic and RAAS Profiles in Patients with Type 2 Diabetes (T2D) and Heart Failure (HF)
HF is associated with decreased renal blood flow and RAAS activation, which may be aggravated in the presence of T2D. The renal arterial-venous gradient for RAAS markers has not be...
Elevated Circulating Levels of Phenylacetylglutamine in Stroke Patients With T2D Are Linked to Specific Gut Microbiota
Elevated Circulating Levels of Phenylacetylglutamine in Stroke Patients With T2D Are Linked to Specific Gut Microbiota
Abstract Background Type 2 diabetes (T2D) aggravates the injury of ischemic stroke (IS). The gut microbiota-related metabolite phenylacetylglutamine (PAGln) has been shown ...
Effect of dapagliflozin on paracetamol-induced hepatotoxicity and nephrotoxicity in type 2 diabetic albino rats
Effect of dapagliflozin on paracetamol-induced hepatotoxicity and nephrotoxicity in type 2 diabetic albino rats
Introduction: paracetamol (PARA) is a worldwide antipyretic and analgesic medication. It has been extensively utilized during the last few years. PARA abuse would lead to liver and...
Phenotyping diabetic cardiomyopathy in Europeans and South Asians
Phenotyping diabetic cardiomyopathy in Europeans and South Asians
AbstractBackgroundThe pathogenesis and cardiovascular impact of type 2 diabetes (T2D) may be different in South Asians compared with other ethnic groups. The phenotypic characteriz...
<b>Genome-Wide Polygenic Risk Score Predicts Incident Type 2 Diabetes in Women with History of Gestational Diabetes</b>
<b>Genome-Wide Polygenic Risk Score Predicts Incident Type 2 Diabetes in Women with History of Gestational Diabetes</b>
<p dir="ltr"><b>Objective</b> Women with a history of gestational diabetes mellitus (GDM) are at increased risk of developing type 2 diabetes (T2D). It remains un...
Tear Fluid Biomarkers and Ocular Surface Parameters in People with Type 2 Diabetes
Tear Fluid Biomarkers and Ocular Surface Parameters in People with Type 2 Diabetes
It is well-known that diabetes is one of the major causes of dry eye disease (DED). As DED can lead to serious ocular surface complications such as punctate keratitis, corneal eros...

Back to Top